(Q38845026)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28393361%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Immune checkpoints and their inhibition in cancer and infectious diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28393361%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28393361%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

Lydia Dyck

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28393361%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

language of work or name

English

0 references

publication date

24 April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28393361%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

17 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28393361%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28393361%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28393361%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

765-779

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28393361%20AND%20SRC:MED&resulttype=core&format=json

Overcoming T cell exhaustion in infection and cancer

17 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Molecular and cellular insights into T cell exhaustion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

T-cell regulation by CD28 and CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Structural analysis of CTLA-4 function in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

The soluble isoform of CTLA-4 as a regulator of T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Differential expression of CTLA-4 among T cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Reversal of the TCR stop signal by CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Targeting T Cell Co-receptors for Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Oncology meets immunology: the cancer-immunity cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Consensus nomenclature for CD8(+) T cell phenotypes in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Reciprocal effects of Th1 and Treg cell inducing pathogen-associated immunomodulatory molecules on anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Treg-cell depletion promotes chemokine production and accumulation of CXCR3(+) conventional T cells in intestinal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Targeting regulatory T cells in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

How tolerogenic dendritic cells induce regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Regulatory T cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Prognostic significance of PD-L1 and PD-L2 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Immune checkpoint combinations from mouse to man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Gauging the Long-Term Benefits of Ipilimumab in Melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

TIGIT predominantly regulates the immune response via regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Blockade of Tim-3 signaling restores the virus-specific CD8⁺ T-cell response in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Cytotoxic T-cell immunity to influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Induction of regulatory cells by helminth parasites: exploitation for the treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

TLR2 directing PD-L2 expression inhibit T cells response in Schistosoma japonicum infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Expression of PD-1/LAG-3 and cytokine production by CD4(+) T cells during infection with Plasmodium parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Expression of the programmed death ligand 1, B7-H1, on gastric epithelial cells after Helicobacter pylori exposure promotes development of CD4+ CD25+ FoxP3+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1 modulates steady-state and infection-induced IL-10 production in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-1/PD-L pathway inhibits M.tb-specific CD4+ T-cell functions and phagocytosis of macrophages in active tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Regulatory T cells: friend or foe in immunity to infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

Mycobacterium tuberculosis Promotes Regulatory T-Cell Expansion via Induction of Programmed Death-1 Ligand 1 (PD-L1, CD274) on Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

7 January 2021

Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

7 January 2021

Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

7 January 2021

The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

7 January 2021

New insights of CTLA-4 into its biological function in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

7 January 2021

TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

7 January 2021

TGF-beta mediates CTLA-4 suppression of cellular immunity in murine kalaazar

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646875

7 January 2021

Identifiers

DOI

10.1002/EJI.201646875

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28393361%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference